181 related articles for article (PubMed ID: 20667972)
1. Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.
Messadi E; Vincent MP; Griol-Charhbili V; Mandet C; Colucci J; Krege JH; Bruneval P; Bouby N; Smithies O; Alhenc-Gelas F; Richer C
FASEB J; 2010 Dec; 24(12):4691-700. PubMed ID: 20667972
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size.
Linz W; Wiemer G; Schölkens BA
Am J Cardiol; 1997 Aug; 80(3A):118A-123A. PubMed ID: 9293964
[TBL] [Abstract][Full Text] [Related]
3. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
Linz W; Wiemer G; Schölkens BA
Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
5. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.
Wollert KC; Studer R; Doerfer K; Schieffer E; Holubarsch C; Just H; Drexler H
Circulation; 1997 Apr; 95(7):1910-7. PubMed ID: 9107180
[TBL] [Abstract][Full Text] [Related]
7. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
[TBL] [Abstract][Full Text] [Related]
8. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.
Rastegar MA; Marchini F; Morazzoni G; Vegh A; Papp JG; Parratt JR
Br J Pharmacol; 2000 Feb; 129(4):671-80. PubMed ID: 10683191
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury.
Wang LX; Ideishi M; Yahiro E; Urata H; Arakawa K; Saku K
Hypertens Res; 2001 Mar; 24(2):179-87. PubMed ID: 11325078
[TBL] [Abstract][Full Text] [Related]
10. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms.
Sato M; Engelman RM; Otani H; Maulik N; Rousou JA; Flack JE; Deaton DW; Das DK
Circulation; 2000 Nov; 102(19 Suppl 3):III346-51. PubMed ID: 11082412
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Stauss HM; Zhu YC; Redlich T; Adamiak D; Mott A; Kregel KC; Unger T
J Cardiovasc Risk; 1994 Oct; 1(3):255-62. PubMed ID: 7621306
[TBL] [Abstract][Full Text] [Related]
12. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.
Qi Y; Zhang J; Cole-Jeffrey CT; Shenoy V; Espejo A; Hanna M; Song C; Pepine CJ; Katovich MJ; Raizada MK
Hypertension; 2013 Oct; 62(4):746-52. PubMed ID: 23959549
[TBL] [Abstract][Full Text] [Related]
13. Developmental regulation of ACE gene expression by endogenous kinins and angiotensin II.
Yosipiv IV; el-Dahr SS
Am J Physiol; 1995 Aug; 269(2 Pt 2):F172-9. PubMed ID: 7544538
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors.
Duka A; Kintsurashvili E; Duka I; Ona D; Hopkins TA; Bader M; Gavras I; Gavras H
Hypertension; 2008 May; 51(5):1352-7. PubMed ID: 18347228
[TBL] [Abstract][Full Text] [Related]
15. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
16. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
17. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
Miki T; Miura T; Ura N; Ogawa T; Suzuki K; Shimamoto K; Iimura O
J Am Coll Cardiol; 1996 Nov; 28(6):1616-22. PubMed ID: 8917279
[TBL] [Abstract][Full Text] [Related]
18. Genetically increased angiotensin I-converting enzyme alters peripheral and renal vascular reactivity to angiotensin II and bradykinin in mice.
Chollet C; Placier S; Chatziantoniou C; Hus-Citharel A; Caron N; Roussel R; Alhenc-Gelas F; Bouby N
Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H350-H358. PubMed ID: 29101168
[TBL] [Abstract][Full Text] [Related]
19. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice.
Campbell DJ; Alexiou T; Xiao HD; Fuchs S; McKinley MJ; Corvol P; Bernstein KE
Hypertension; 2004 Apr; 43(4):854-9. PubMed ID: 14769811
[TBL] [Abstract][Full Text] [Related]
20. Type 2 bradykinin-receptor antagonism does not modify kinin or angiotensin peptide levels.
Campbell DJ; Kladis A; Briscoe TA; Zhuo J
Hypertension; 1999 May; 33(5):1233-6. PubMed ID: 10334817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
